You are here: Industry Insights > Market News > Zydus’ Nesher Pharma gets US FDA nods for influenza drug

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate

Neohesperidin

Advantame

Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench

Pharma and Food Grade, USP/FCC Neotame Sweetener E961

Trilobatin

Zydus’ Nesher Pharma gets US FDA nods for influenza drug

expressbpdSeptember 19, 2017

Tag: Zydus’ Nesher Pharma , US FDA , influenza drug

Favorites

The drug will be produced at Nesher Pharmaceuticals manufacturing facility located at St Louis, US

Zydus Cadila’s Nesher Pharmaceuticals, a subsidiary of its US arm, has received final approval from the US health regulator to market Oseltamivir powder for oral suspension 6 mg/ml which is used in treatment and prevention of influenza.

The drug will be produced at Nesher Pharmaceuticals manufacturing facility located at St Louis, US, Zydus Cadila said.

The group now has more than 150 approvals and has so far filed over 300 Abbreviated New Drug Applications (ANDAs) since the commencement of the company’s filing process.

Previous:Fosun Pharma to acquire 74 per cent stake in Gland Pharma

Next:Lupin appoints Jim Loerop as Chief Corporate Development Officer

Zydus’ Nesher Pharma gets US FDA nods for influenza drug

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may like
More>>

Zydus’ Nesher Pharma gets US FDA nods for influenza drug

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may likeMore>>

You may like
More>>